Piperacillin-Tazobactam

Studies highlight prevalence of carbapenem-resistant Gram-negative infections, particularly Acinetobacter baumannii and Pseudomonas aeruginosa, and discuss treatment strategies, including ceftolozane-tazobactam and polymyxin-based regimens, with focus on outcomes and resistance trends.

Antimicrobial resistance (AMR) challenges health systems worldwide, driven by lack of access to first-line antibiotics. Shortages of off-patent antibiotics in the EU lead to increased use of broad-spectrum antibiotics and potential harm to patients. Supply chain insecurity, primarily due to concentrated manufacturing in India and China, exacerbates these shortages. Policy options discussed include administrative and regulatory levers, purchasing arrangements, product mapping and stockpiling, and strengthening manufacturing capacity to improve access to existing antibiotics.

ICMR study finds Klebsiella pneumoniae and Acinetobacter baumannii, leading causes of bloodstream infections, are resistant to imipenem among ICU patients. Staphylococcus aureus and Enterococcus faecium also show resistance to oxacillin and vancomycin, respectively. Acinetobacter spp is the most common pathogen for ventilator-associated pneumonia. High resistance rates are observed in E. coli and Klebsiella pneumoniae for carbapenem, fluoroquinolones, and third-generation cephalosporins.